Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis

NCT: NCT04807842 · RECRUITING

NCT IDNCT04807842
StatusRECRUITING
Start Date2021-06-11
Completion2026-12-01
SponsorBioClin BV (INDUSTRY)
First posted
Last updated

Brief Summary

This is a randomized, double-blind, placebo-controlled clinical investigation. The objective of the study is to confirm the efficacy of Multi-Gyn ActiGel Plus to treat BV as compared to a placebo control. Treatment arm 1: Multi-Gyn ActiGel Plus Treatment arm 2: placebo gel Both the Multi-Gyn ActiGel Plus and the placebo will be applied twice a day for 7 consecutive days. Visit 2 will be performed at 3 weeks after start of treatment A phone call will take place, at 5 weeks after start of treatment for subject with clinical cure at Visit 2. The total duration per subject is estimated 5 weeks and the total study duration is 13 months. Sample size is 100 subjects per treatment arm.

Frequently Asked Questions

What is Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis?

Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis is a clinical trial registered under NCT04807842. Current status: RECRUITING.

What is the status of NCT04807842?

The current status of NCT04807842 (Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis) is: RECRUITING.

When did Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis start?

Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis started on 2021-06-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑